

# **Test Definition: FLEC**

Flecainide, Serum

## **Overview**

#### **Useful For**

Optimizing dosage

Assessing flecainide toxicity

Monitoring compliance

#### **Method Name**

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

#### **NY State Available**

Yes

# **Specimen**

## **Specimen Type**

Serum Red

## **Specimen Required**

**Collection Container/Tube:** Red top **Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1.5 mL **Collection Instructions:** 

- 1. Draw blood immediately before next scheduled dose.
- 2. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.

#### **Forms**

If not ordering electronically, complete, print, and send a <u>Therapeutics Test Request</u> (T831) with the specimen.

# **Specimen Minimum Volume**

0.5 mL

## **Reject Due To**

Gross	ОК
hemolysis	
Gross lipemia	ОК
Gross icterus	ОК



# **Test Definition: FLEC**

Flecainide, Serum

### **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum Red	Refrigerated (preferred)	28 days	
	Ambient	28 days	
	Frozen	28 days	

## Clinical & Interpretive

#### **Clinical Information**

Flecainide (Tambocor) is a Class I cardiac antiarrhythmic agent indicated for treatment of paroxysmal supraventricular dysrhythmia, paroxysmal atrial fibrillation/flutter, and life-threatening ventricular dysrhythmias. After oral administration, flecainide is almost completely absorbed and peak concentrations are attained in approximately 3 hours. The half-life averages approximately 20 hours but is widely variable (12 to 27 hours), and steady-state concentrations are typically achieved in approximately 5 days. Flecainide is eliminated from blood by hepatic metabolism, as well as renal clearance; significant changes in either organ system will cause impaired clearance. Common adverse effects include dizziness, visual disturbances, and dyspnea. Mild-to-moderate toxicity is associated with dizziness, visual disturbances, headache, nausea, fatigue, palpitations, and chest pain. Visual hallucinations and dysarthria may occur at toxic serum concentrations. Death can occur from hypotension, respiratory failure, and asystole.

#### Reference Values

**Trough Value** 

0.2-1.0 mcg/mL: Therapeutic concentration

>1.0 mcg/mL: Toxic concentration

## Interpretation

Flecainide is most effective in premature ventricular contractions suppression at serum concentrations in the range of 0.2 to 1.0 mcg/mL.

Serum concentrations above 1.0 mcg/mL are associated with a high rate of cardiac adverse experiences such as conduction defects or bradycardia.

### **Cautions**

Specimens that are obtained from gel tubes or anticoagulate collections can cause assay interference.

#### Clinical Reference

- 1. Rifai N, Horwath AR, Wittwer CT: In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018
- 2. Josephson ME, Buxton AE, Marchlinski FE: The tachyarrhythmias: tachycardias. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 12th ed. McGraw-Hill Book Company; 1991:915
- 3. Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem. 1998 May;44(5):1096-1099



# **Test Definition: FLEC**

Flecainide, Serum

#### **Performance**

#### **Method Description**

Protein is precipitated from serum and following centrifugation the supernatant is diluted and analyzed by liquid chromatography-tandem mass spectrometry. (Unpublished Mayo method)

## **PDF Report**

No

# Day(s) Performed

Monday through Saturday

#### **Report Available**

2 to 5 days

#### **Specimen Retention Time**

14 days

# **Performing Laboratory Location**

Rochester

# **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

#### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

## **CPT Code Information**

80181

#### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
FLEC	Flecainide, S	3638-4

Result ID	Test Result Name	Result LOINC® Value
9243	Flecainide, S	3638-4